Saturday, November 09, 2024 5:54:03 PM
@ADHCMANAGEMENT
$ADHC
Hello I am Zachary Smith , founder of Glucoguard, We are prepping a series of videos for You Tube explaining the Glucoguard technology with a focus on how AI & CGM manages diabetes. Focus is On IR, PR and Patient Advocacy creating global awareness.
Glucoguard, a Division of ADHC, Completes AI Based Mobile Application and Design Outline (MADO) for Dexcom API Integration
Press Release | 10/29/2024
Del Mar, California--(Newsfile Corp. - October 29, 2024) - American Diversified Holdings Corporation (OTC Pink: ADHC) announced today that Glucoguard, has competed the "MADO" Mobile Application and Design Outline as required for the Dexcom API Integration.
This outline has been submitted to the software design team to finalize the integration process through the Dexcom Development Partner Program.
The proprietary AI based algorithm outlined in the MADO is the backbone of the Glucoguard App and the foundation for the diabetes management system. The main AI component analyzes current blood sugar levels and will predictively treat lows before a potential catastrophic hypoglycemic event can occur.
Glucoguard is developing a mobile application to enable and support the functionality of the patent-pending diabetes management system. The system integrates with Dexcom's Continuous Glucose Monitoring (CGM) technology to track blood glucose levels and then respond to fluctuations in real-time, as a preemptive solution to the potential catastrophic effects of hypoglycemia.
The mobile app will serve as an essential tool for users, connecting them directly to the Glucoguard device. The device provides glucose to patients when the AI-based Algorithm detects critical changes in glucose levels, preventing dangerous episodes of Hypoglycemia (low blood sugar). By using a state-of-the-art Artificial Intelligence algorithm to ensure Glucoguard offers a best-in-class approach to diabetes management.
"Events are moving rapidly with the Glucoguard Team. Once the full API integration process is complete, we will move to prototype development and full software/hardware integration," commented Glucoguard/ADHC. "Glucoguard will soon be on the map in the diabetes management sector, utilizing AI to elevate Continuous Glucose Management to the next level treatment of diabetic patients."
Shareholders will be notified as developments are finalized in the near future.
About IMD Solutions, Inc.
IMD Solutions, Inc. is a Nevada-based medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, IMD Solutions is at the forefront of diabetes management technology.
For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
Email: info@GlucoGuardSleep.com
About AMERICAN DIVERSIFIED HOLDINGS CORPORATION
www.UniversalWellnessAI.com
www.UniversalWellnessShop.com
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com
Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
$ADHC
Hello I am Zachary Smith , founder of Glucoguard, We are prepping a series of videos for You Tube explaining the Glucoguard technology with a focus on how AI & CGM manages diabetes. Focus is On IR, PR and Patient Advocacy creating global awareness.
Glucoguard, a Division of ADHC, Completes AI Based Mobile Application and Design Outline (MADO) for Dexcom API Integration
Press Release | 10/29/2024
Del Mar, California--(Newsfile Corp. - October 29, 2024) - American Diversified Holdings Corporation (OTC Pink: ADHC) announced today that Glucoguard, has competed the "MADO" Mobile Application and Design Outline as required for the Dexcom API Integration.
This outline has been submitted to the software design team to finalize the integration process through the Dexcom Development Partner Program.
The proprietary AI based algorithm outlined in the MADO is the backbone of the Glucoguard App and the foundation for the diabetes management system. The main AI component analyzes current blood sugar levels and will predictively treat lows before a potential catastrophic hypoglycemic event can occur.
Glucoguard is developing a mobile application to enable and support the functionality of the patent-pending diabetes management system. The system integrates with Dexcom's Continuous Glucose Monitoring (CGM) technology to track blood glucose levels and then respond to fluctuations in real-time, as a preemptive solution to the potential catastrophic effects of hypoglycemia.
The mobile app will serve as an essential tool for users, connecting them directly to the Glucoguard device. The device provides glucose to patients when the AI-based Algorithm detects critical changes in glucose levels, preventing dangerous episodes of Hypoglycemia (low blood sugar). By using a state-of-the-art Artificial Intelligence algorithm to ensure Glucoguard offers a best-in-class approach to diabetes management.
"Events are moving rapidly with the Glucoguard Team. Once the full API integration process is complete, we will move to prototype development and full software/hardware integration," commented Glucoguard/ADHC. "Glucoguard will soon be on the map in the diabetes management sector, utilizing AI to elevate Continuous Glucose Management to the next level treatment of diabetic patients."
Shareholders will be notified as developments are finalized in the near future.
About IMD Solutions, Inc.
IMD Solutions, Inc. is a Nevada-based medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, IMD Solutions is at the forefront of diabetes management technology.
For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
Email: info@GlucoGuardSleep.com
About AMERICAN DIVERSIFIED HOLDINGS CORPORATION
www.UniversalWellnessAI.com
www.UniversalWellnessShop.com
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com
Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
Recent ADHC News
- American Diversified Holdings Operating Division GlucoGuard Retains Global Contract Research Organization (CRO) to Begin Patient Studies as Required by the FDA • Newsfile • 04/01/2026 12:30:00 PM
- American Diversified Holdings Corporation (ADHC) Announces Internal Technology Initiative Within Universal Wellness AI Division • Newsfile • 01/06/2026 02:00:00 PM
- GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program • Newsfile • 11/25/2025 02:00:00 PM
- GlucoGuard Receives $43 Million Enterprise Valuation From Prominent CFA Led Harbinger Research • Newsfile • 11/04/2025 02:00:00 PM
- American Diversified Holdings Corporation Receives $5,000,000 (Five Million) Financing Commitment from an Institutional Investment Fund • Newsfile • 10/16/2025 01:00:00 PM
- GlucoGuard Receives Scope of Work (SOW) Proposal from Arete Bioscience for FDA Recommended Sleep Study • Newsfile • 10/14/2025 10:00:00 AM
